Boobalan Pachaiyappan
Stock Analyst at Roth MKM
(1.24)
# 3,419
Out of 4,734 analysts
8
Total ratings
50%
Success rate
-8.66%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Boobalan Pachaiyappan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRNA Verona Pharma | Initiates: Buy | $68 | $51.89 | +31.05% | 1 | Jan 10, 2025 | |
| CING Cingulate | Initiates: Buy | $12 | $4.76 | +152.10% | 1 | Jan 10, 2025 | |
| RVPH Reviva Pharmaceuticals Holdings | Initiates: Buy | $7 | $1.77 | +295.48% | 1 | Jan 10, 2025 | |
| GANX Gain Therapeutics | Maintains: Buy | $7 | $2.28 | +207.02% | 2 | Dec 24, 2024 | |
| CRVO CervoMed | Initiates: Buy | $45 | $2.11 | +2,032.70% | 1 | Dec 5, 2024 | |
| TRDA Entrada Therapeutics | Initiates: Buy | $29 | $12.69 | +128.53% | 1 | Dec 5, 2024 | |
| LGVN Longeveron | Initiates: Buy | $10 | $1.70 | +488.24% | 1 | Dec 5, 2024 |
Verona Pharma
Jan 10, 2025
Initiates: Buy
Price Target: $68
Current: $51.89
Upside: +31.05%
Cingulate
Jan 10, 2025
Initiates: Buy
Price Target: $12
Current: $4.76
Upside: +152.10%
Reviva Pharmaceuticals Holdings
Jan 10, 2025
Initiates: Buy
Price Target: $7
Current: $1.77
Upside: +295.48%
Gain Therapeutics
Dec 24, 2024
Maintains: Buy
Price Target: $7
Current: $2.28
Upside: +207.02%
CervoMed
Dec 5, 2024
Initiates: Buy
Price Target: $45
Current: $2.11
Upside: +2,032.70%
Entrada Therapeutics
Dec 5, 2024
Initiates: Buy
Price Target: $29
Current: $12.69
Upside: +128.53%
Longeveron
Dec 5, 2024
Initiates: Buy
Price Target: $10
Current: $1.70
Upside: +488.24%